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Abstract
Background: The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) was the biggest
ovarian cancer screening trial to date. A non-significant effect of screening on ovarian cancer was reported, but the
authors noted a potential delayed effect of screening, and suggested the need for four years further follow-up.
There are no UK-based cost-effectiveness analyses of ovarian cancer screening. Hence we assessed the lifetime
outcomes associated with, and the cost-effectiveness of, screening for ovarian cancer in the UK, along with the
value of further research.
Methods: We performed a model-based economic evaluation. Effectiveness data were taken from UKCTOCS, which
considered strategies of multimodal screening (MMS), ultrasound screening (USS) and no screening. We conducted
systematic reviews to identify the remaining model inputs, and performed a rigorous and transparent prospective
evaluation of different methods for extrapolating the effect of screening on ovarian cancer mortality. We considered
costs to the UK healthcare system and measured effectiveness using quality-adjusted life years (QALYs). We used value
of information methods to estimate the value of further research.
Results: Over a lifetime, MMS and USS were estimated to be both more expensive and more effective than no screening.
USS was dominated by MMS, being both more expensive and less effective. Compared with no screening, MMS cost
on average £419 more (95% confidence interval £255 to £578), and generated 0.047 more QALYs (0.002 to 0.088). The
incremental cost-effectiveness ratio (ICER) comparing MMS with no screening was £8864 per QALY (£2600 to £51,576).
Alternative extrapolation methods increased the ICER, with the highest value being £36,769 (£13,888 to dominated
by no screening). Using the UKCTOCS trial horizon, both MMS and USS were dominated by no screening, as they
produced fewer QALYs at a greater cost. The value of research into eliminating all uncertainty in long-term effectiveness
was estimated to be worth up to £20 million, or approximately £5 million for four years follow-up.
Conclusions: Screening for ovarian cancer with MMS is both more effective and more expensive than not screening.
Compared to national willingness to pay thresholds, lifetime cost-effectiveness is promising, but there remains
considerable uncertainty regarding extrapolated long-term effectiveness.
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Background
Ovarian cancer is the fifth highest cause of cancer deaths
in women in the UK [1]. Survival is strongly associated
with the stage of cancer at diagnosis, with women pre-
senting with the most advanced stage of disease having
one-year survival rates of 53% compared to 97% for
women presenting with the least advanced stage of
disease [2]. The majority of women with ovarian cancer
present symptomatically with advanced disease [3].
Hence it has been hypothesised that screening has the
potential to detect ovarian cancers earlier, which may in
turn lead to improvements in survival.
The United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) is the largest ovarian
cancer screening trial to date [4]. It evaluated the per-
formance of two screening strategies compared to no
screening. The ultrasound screening (USS) strategy in-
volved first line screening with a transvaginal ultrasound
scan (TVS), carried out by certified sonographers or
National Health Service (NHS) staff with similar experi-
ence (type 1). Second line screening involved a TVS per-
formed by more experienced staff (type 2), including
senior sonographers, radiologists or experienced gynae-
cologists. The multimodal screening (MMS) strategy
involved first line screening with the CA-125 blood test
interpreted using a risk of ovarian cancer algorithm
(ROCA) [5] and second line screening with a type 2
TVS. Between April 2001 and October 2005, 202,638
women were randomised to one of the three trial arms:
101,359 to no screening, 50,639 to USS and 50,640 to
MMS. Screening was performed until 31 December 2011,
with a median of 11.1 years follow-up. The primary out-
come was ovarian cancer mortality, with results showing
that MMS was associated with a 15% relative reduction
(95% confidence interval –3% to 30%, p = 0.10) [6]. A rela-
tive reduction of 11% was observed for USS (–7% to 27%,
p = 0.21) [6]. Whilst neither of the mortality reductions
reached conventional levels of statistical significance, the
study authors noted a potential delayed effect of screen-
ing, and called for four additional years of follow-up to
fully assess the extent of the mortality reductions [7].
Our model-based economic evaluation had two aims.
The first was to evaluate the potential cost-effectiveness
of screening for ovarian cancer in the UK. The second
was to estimate the value of further research into
ovarian cancer screening, including the value of reducing
uncertainty in the long-term effect of screening on
mortality.
Methods
Estimates of clinical effectiveness
We conducted a systematic review to identify any relevant
screening trials in addition to the UKCTOCS. This identi-
fied an existing systematic review and meta-analysis by
Reade et al. [8]. We did not identify any additional trials
beyond those identified by Reade et al. [8], although two
additional UKCTOCS publications were available [6, 9].
The UKCTOCS trial results are likely to supersede those
of previous screening studies due to evolutions in the use
of blood tests for screening. Hence effectiveness data were
taken from the UKCTOCS study alone.
We used results in the public domain to estimate ovar-
ian cancer incidence and mortality for all three trial arms.
We digitised Kaplan-Meier curves [6] using EnGauge soft-
ware and replicated individual patient data in R using the
method described by Guyot et al. [10]. This replicated data
covered the time horizon of the UKCTOCS trial, with a
median follow-up of 11.1 years, and was validated by com-
paring model estimates of cancers diagnosed and ovarian
cancer mortality at 11 years with the trial estimates. For
the economic evaluation, estimates of lifetime clinical
effectiveness were required. Hence we carried out a pro-
spective evaluation of different methods for extrapolating
the UKCTOCS trial data. The UKCTOCS triallists ana-
lysed the effects of screening on mortality as time-varying
hazard ratios using Royston-Parmar (R-P) models [11].
For consistency, the base-case extrapolation of mortality
data used R-P models to estimate the hazard of mortality
for no screening, and hazard ratios for MMS and USS (both
relative to no screening). Hazards and hazard ratios were
extrapolated using time-series (exponential smoothing)
methods [12].
The use of standard parametric models was also
assessed in two structural uncertainty analyses: one
using separate standard parametric models for each trial
arm, and one using the same parametric model for all
three arms. Five parametric models were considered
(exponential, Weibull, Gompertz, log-logistic and log-
normal), and the choice between the models was based
on minimising the Bayesian information criterion, which
was either calculated separately for each trial arm or
combined across the three arms. We used a novel model
discrepancy method to explore the potential impact of
structural uncertainty associated with the extrapolation
of long-term outcomes in an additional structural uncer-
tainty analysis [13]. This had the dual effect of reducing
the effectiveness of both MMS and USS during the
extrapolated period (as compared with the base-case
estimates) and also increasing the uncertainty in these
estimates. The model discrepancy tested was a cumula-
tive 5% decrease in the effect of screening per year, with
a standard deviation of 0.05. Incidence data were extrap-
olated using standard parametric survival models. Esti-
mates of the number of false positives (per cancer
diagnosed) were taken from the UKCTOCS [6].
Other-cause mortality was taken from the UKCTOCS
publication (Appendix Web Table 6 of Jacobs et al 2016
[6]), which presented the number of deaths and women-
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years by screening arm. As there was no evidence that
other-cause mortality varied with screening arm, this
evidence was pooled to obtain an overall annual value of
0.61% (13,296 deaths from 2,194,447 women-years).
Other-cause mortality was extrapolated using National
Life Tables [14], and assuming that women would be on
average 60 when they enter the model (so that after the
within-trial period has ended, women would be on aver-
age 72 years old). This approach to separately modelling
mortality due to ovarian cancer and mortality due to
other causes is consistent with existing economic evalua-
tions of ovarian cancer [15, 16].
Utility data
We performed a systematic review which identified two
published systematic reviews [8, 17] and two studies
which provided ovarian cancer utility values [9, 18]. The
systematic review of Hess et al. [17] focussed on the
treatment of ovarian cancer. There was a lack of consist-
ent evidence on the effect of different treatment strat-
egies on women’s health-related quality of life (HRQoL),
which may be due to the heterogeneity in the utility
measures used, treatments received and populations
considered. However, there was a statistically significant
increase in HRQoL after completing treatment, com-
pared with at the start of treatment. The systematic re-
view by Reade et al. was the previously discussed review
of trials [8]. This identified three trials which evaluated
the impact of screening on HRQoL. Reade et al. con-
cluded that there was high-quality evidence to suggest
that screening for ovarian cancer does not have an im-
pact on HRQoL. This conclusion was supported by the
two identified studies [9, 18]. Of these, the study by
Havrilesky et al. also reported time trade-off valuations
of utility for women diagnosed with early and advanced
ovarian cancer [18]; these valuations were used to gener-
ate stage-specific disutility values for newly diagnosed
ovarian cancer. We assumed that this disutility related
to treatment, and only lasted for one year, after which
women’s HRQoL returned to that of the general popula-
tion. We further assumed that there was no disutility
associated with receiving a screen, but that women receiv-
ing treatment following a false positive result would experi-
ence the same disutility as a woman with Stage 1 cancer.
Costs and resource use
We derived costs and resource usage from sources
including clinical guidelines, literature, data from the
English Cancer Registries and estimates provided by
multidisciplinary teams responsible for the management
and treatment of ovarian cancer.
Resource use for ovarian cancer screening was taken
from the UKCTOCS [4]. There are no routine estimates
for either the cost of the CA-125 blood test or the
ROCA algorithm. For the former we used cost estimates
developed for the Early Cancer Detection Consortium
[19]. As the ROCA was developed and trialled with sup-
port from public and charitable monies, we assumed
that using the ROCA would not lead to any increase in
the cost of a screen within the UK setting. The costs of
type 1 and type 2 TVSs were derived from national ref-
erence costs.
Initial estimates for the cost of ovarian cancer diagno-
sis and treatment were taken from the Incisive report,
which was commissioned by Cancer Research UK to
examine the financial implications of achieving earlier diag-
nosis of colorectal, lung and ovarian cancers [20]. These
estimates were supplemented by treatment data from the
English Cancer registries and shared with two multidiscip-
linary teams (based in Sheffield and Birmingham), who
refined the estimates of cost and resource use. These
were used to derive estimates for the cost of diag-
nosing and treating ovarian cancer, based on stage at
diagnosis.
An overview of the key model inputs is provided in
Table 1. Further details on the derivation of utility and
cost values, along with details of all the search strategies,
are provided in Additional file 1.
Cost-effectiveness modelling methods
The health economic model was a cohort-level Markov
model developed in Microsoft Excel®, with the perspec-
tive of the NHS and Personal Social Services, a lifetime
horizon and an annual cycle. Details on the derivation of
annual transition probabilities from time-series and
parametric survival models are provided in Additional
file 1. Costs were reported in 2013/2014 pound sterling.
The primary outcome was the incremental cost-
effectiveness ratio (ICER) measured by the incremental
cost per quality-adjusted life years (QALYs) gained. Both
costs and QALYs were discounted at 3.5% per annum as
recommended by the National Institute for Health and
Care Excellence in England [21]. The model structure
included six health states corresponding to the screening
status of women without diagnosed ovarian cancer, diag-
nosed ovarian cancer stratified by the first and subse-
quent years of diagnosis, and mortality due to either
ovarian cancer or other causes. The half-cycle correction
was employed. A model schematic is provided in Fig. 1.
Estimates of cost-effectiveness were obtained by run-
ning the health economic model probabilistically over
5000 Monte Carlo samples, with percentile-based confi-
dence intervals. In addition to the previously described
structural uncertainty analyses, univariate sensitivity
analyses were undertaken to examine the impact of
individual model inputs on cost-effectiveness. A full
description of these sensitivity analyses is provided in
Additional file 1.
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As part of the uncertainty analysis, value of informa-
tion methods were used to estimate the value of further
research. These methods assess the impact of uncer-
tainty in the model results on decision uncertainty and
the subsequent opportunity cost that is due to decision
uncertainty. The population expected value of perfect in-
formation (EVPI) provides an estimate of how much
should be spent to eliminate all decision uncertainty in
the cost-effectiveness results. The expected value of per-
fect parameter information (EVPPI) estimates the contri-
bution of each model input to the EVPI [22]. Estimates
were obtained from the online Sheffield Accelerated
Value of Information application (http://savi.shef.ac.uk/
SAVI/), using standard methods for EVPI [23, 24] and
EVPPI methods recently reported by Strong et al. [22]. It
was assumed that the annual number of women affected
by the decision about whether or not to fund screening
was 7,121,000, equivalent to the Office for National
Statistics Mid-2010 Population Estimates for women
aged from 50 to –74 [25]. This value was adjusted by the
uptake to UKCTOCS and subsequent compliance with
screening [6] to give a value of 1,045,914. A time hori-
zon for the decision of one year was used, as the popula-
tion value implicitly covers all of the relevant years.
Results
Base-case cost-effectiveness results
The lifetime cost-effectiveness results for the three
screening strategies are presented in Table 2. Compared
to no screening, both active screening strategies were
predicted to increase QALYs but also increased costs. The
estimated total lifetime average cost per woman for no
screening was £179 (95% confidence interval £137 to £242).
Screening with MMS increased costs by £419 (£255 to
£578), whilst for USS the increase was £646 (£386 to £973).
The average QALYs accrued under no screening were
14.290 (5.159–15.907), with increases of 0.047 (0.002–0.088)
and 0.007 (–0.042 to 0.049) for MMS and USS respectively.
The ICER comparing MMS with no screening was £8864
per QALY (£2600 to £51,576). Use of USS was dominated
Table 1 Key model inputs
Mean Distribution 95% confidence interval
Cost parameters
Multimodal screening (drop-outs) £54 Beta £33 to £74
Multimodal screening (complete screening) £61 Hybrida £37 to £83
Ultrasound screening (drop-outs) £56 Gamma £29 to £92
Ultrasound screening (complete screening) £61 Hybrida £31 to £100
Screening invitation (either strategy) £2.09 Gamma £1.70 to £2.52
Diagnosis: Borderline £110 Gamma £91 to £135
Diagnosis: Stage 1 ovarian cancer £116 Gamma £90 to £133
Diagnosis: Stage 2 ovarian cancer £126 Gamma £94 to £140
Diagnosis: Stage 3 ovarian cancer £126 Gamma £102 to £152
Diagnosis: Stage 4 ovarian cancer £112 Gamma £102 to £152
Treatment: Borderline £3000 Gamma £1161 to £5696
Treatment: Stage 1 ovarian cancer £6961 Gamma £4856 to £9438
Treatment: Stage 2 ovarian cancer £7325 Gamma £5211 to £9795
Treatment: Stage 3 ovarian cancer £9016 Gamma £6866 to £11,454
Treatment: Stage 4 ovarian cancer £5892 Gamma £3823 to £8402
End of life cost: ovarian cancer £7080 Gamma £5761 to £8533
Utility parameters
Utility cancer free 0. 900 Beta 0.325 to 1
Disutility Stage 1 ovarian cancer or false positive result 0.200 Beta 0.044 to 0.437
Disutility Stage 2 ovarian cancer 0.325 Beta 0.214 to 0.534
Disutility Stage 3 ovarian cancer 0.413 Beta 0.329 to 0.600
Disutility Stage 4 ovarian cancer 0. 455 Beta 0.413 to 0.601
Number of false positives per cancer identified
Multimodal screening 2.302 Beta 2.188 to 2.412
Ultrasound screening 9.963 Beta 9.813 to 10.104
aMixture of gamma and beta distributions; see Additional file 1 for more details
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by MMS, being both more expensive and less effective.
Compared to a strategy of no screening, both MMS and
USS resulted in increases in life expectancy of 0.58% and
0.28% respectively, equating to an extra 7.39 (1.58–12.65)
and 3.58 (–3.46 to 8.76) weeks. With no screening, 3.19%
(1.98–5.17%) of women would die from ovarian cancer. For
MMS and USS, this proportion was estimated to reduce to
1.41% (0.56–3.46%) and 2.35% (1.06–5.21%) respectively.
The estimated ICER for MMS (£8864) is lower than both
the traditional willingness to pay levels for the NHS of
£20,000 per QALY [26] and the recently suggested value of
£13,000 per QALY [27]. For both MMS and USS, the cost
of screening was approximately £400 per woman. Compared
to a strategy of no screening, both active screening strategies
resulted in increased treatment costs (due to the additional
treatment of false positives) but lower end-of-life costs (due
to fewer ovarian cancer deaths).
A comparison of 11-year estimates with the UKCTOCS
results (Table 2) shows close agreement for both the pro-
portion of cancers diagnosed and the proportion of deaths
due to ovarian cancer. At this time horizon, both MMS
and USS were dominated by a strategy of no screening,
being both more expensive and generating fewer QALYs,
as the dis-benefits of screening — earlier treatment of
asymptomatic women and treatment of false positives —
outweighed the mortality reduction. Both MMS and USS
remained dominated by no screening at 11 years in an
exploratory analysis that removed the impact of false
positives.
Extrapolation assumptions
When using separate parametric models for each trial
arm, the log-normal was selected for both MMS and
USS, whilst the Weibull was selected for no screening.
When fitting the same model to all three trial arms, the
log-normal was selected. Figure 2 displays estimates of
cumulative ovarian cancer mortality for MMS and no
screening for the extrapolation approaches considered,
with cost-effectiveness results presented in Table 3. The
use of parametric curves for extrapolation results in a
lower estimated lifetime number of ovarian cancer
deaths across all three trial arms, with the largest reduc-
tions observed for the no screening group (reduced from
3.19% to 1.99% or 1.49% for the Weibull and log-normal
models respectively). This affects the ICER for MMS,
which relative to no screening increases from £8864 in
the base case to either £18,372 or £36,769 depending on
the parametric assumptions employed. Introducing a
model discrepancy increased the ICER for MMS relative
to no screening to £12,643.
Estimates of uncertainty and the value of further research
The probability of each of the screening strategies being
cost-effective is displayed in Fig. 3 for maximum willing-
ness to pay (WtP) values between £0 and £40,000 per
QALY gained, with EVPI estimates on a separate axis. A
WtP value indicates the monetary equivalent that is at-
tributed to a QALY. For example, a willingness to pay of
£20,000 indicates that a decision-maker is willing to pay
£20,000 per QALY gained.
As WtP increases, more weight is given to effective-
ness and the probability of MMS being cost-effective
increases. At a WtP value of £13,000 the probability of
MMS being cost-effective is 74.2%; at a value of £20,000
it is 86.2%. Population EVPI reaches a maximum at a
WtP threshold of about £9000, with a value of approxi-
mately £90 million. Estimates of EVPPI, taken at a WtP
of £20,000, show that the key drivers of decision uncer-
tainty are long-term mortality effectiveness estimates for
MMS compared to no screening, and the HRQoL for
women with ovarian cancer. These contribute to 53%
and 22% of the decision uncertainty respectively; it
would be worth spending approximately £20 million to
eliminate all of the uncertainty in the long-term effect-
iveness of screening.
Fig. 1 Schematic of the health economic model
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Full details of the sensitivity analyses results are pro-
vided in Additional file 1. Of these analyses, cost-
effectiveness results were sensitive to the inclusion of a
disutility due to screening, the inclusion of a cost for the
ROCA Test and the assumed cost of MMS. Including an
annual disutility due to screening of 0.01 (equivalent to
experiencing a disutility of 0.06 for a month) led to both
screening strategies being dominated by no screening.
With a disutility of 0.005 (equivalent to experiencing a
disutility of 0.06 for a month) the ICER for MMS com-
pared to no screening increased by more than 200% to
£26,173 per QALY. Including a cost for the ROCA Test
led to MMS being more expensive than USS. However,
USS was extendedly dominated by the combination of
no screening and MMS (ICER for USS vs no screening:
£64,231 per QALY). The ICER for MMS compared to
Table 2 Base-case probabilistic cost-effectiveness results: lifetime average costs and QALYs per woman
Model lifetime results No screening MMS USS
Costs £179 £598 £824
(95% confidence interval) (£137 to £242) (£434 to £758) (£566 to £1154)
Incremental costs – £419 £646
(95% confidence interval) (£255 to £578) (£386 to £973)
QALYs 14.290 14.357 14.297
(95% confidence interval) (5.159 to 15.907) (5.168 to 15.959) (5.147 to 15.926)
Incremental QALYs – 0.047 0.007
(95% confidence interval) (0.002 to 0.088) (–0.042 to 0.049)
ICER per QALY – £8864 vs no screening Dominated by MMS
(95% confidence interval) (£2600 to £51,576)
Life years 24.660 24.803 24.729
(95% confidence interval) (24.543 to 24.741) (24.668 to 24.872) (24.554 to 24.822)
Incremental life years – 0.142 0.069
(95% confidence interval) (0.03 to 0.24) (–0.07 to 0.17)
Ovarian cancer deaths 3.19% 1.41% 2.35%
(95% confidence interval) (1.98% to 5.17%) (0.56% to 3.46%) (1.06% to 5.21%)
Incremental OC deaths – –1.77% –0.83%
(95% confidence interval) (–3.38% to –0.19%) (–2.39% to 1.26%)
Model 11-year results No screening MMS USS
Costs £58 £510 £612
(95% confidence interval) (£49 to £67) (£350 to £660) (£399 to £886)
QALYs 8.250 8.247 8.239
(95% confidence interval) (2.823 to 9.163) (2.820 to 9.162) (2.801 to 9.157)
Life years 11.093 11.093 11.093
(95% confidence interval) (11.090 to 11.096) (11.086 to 11.098) (11.089 to 11.097)
Cancers diagnosed 0.59% 0.65% 0.61%
(95% confidence interval) (0.55% to 0.64%) (0.58% to 0.72%) (0.55% to 0.69%)
Ovarian cancer deaths 0.34% 0.31% 0.33%
(95% confidence interval) (0.29% to 0.41%) (0.21% to 0.44%) (0.26% to 0.41%)
Observed trial results No screening MMS USS
Cancers diagnosed 0.62% 0.67% 0.62%
(95% confidence interval) (0.58% to 0.67%) (0.60% to 0.74%) (0.56% to 0.69%)
Ovarian cancer deaths 0.34% 0.29% 0.30%
(95% confidence interval) (0.31% to 0.38%) (0.25% to 0.34%) (0.26% to 0.36%)
OC ovarian cancer, QALYs quality-adjusted life years
Costs and QALYs are discounted, life years are not. Incremental values are relative to no screening
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no screening increased by 260% to £30,552. Using the high
cost estimate for MMS (with no ROCA cost) led to a rela-
tive increase in the ICER for MMS of 23%, whilst using the
low estimate led to a relative reduction of 40%. Assuming
that diagnosis in primary care has the same false-positive
rate as MMS leads to a 21% relative reduction in the ICER
for MMS. With the exception of the screening disutilities,
for each of the sensitivity analyses considered, the corre-
sponding ICER remained below the £13,000 WtP threshold.
Discussion
Our two aims were to evaluate the lifetime cost-
effectiveness of ovarian cancer screening and the value
of further research. The results of our economic evalu-
ation suggest that either an MMS or USS screening
strategy is likely to result in health benefits when com-
pared to no screening, but at increased costs. Screening
using MMS is estimated to be both more effective and
cheaper than USS. The base-case lifetime ICER compar-
ing MMS against no screening was estimated to be
£8864 per QALY (95% confidence interval £2600 to
£51,576). Based on an 11-year time horizon, both MMS
and USS are dominated by a strategy of no screening.
Value of information analyses suggested that at a will-
ingness to pay of £20,000 per QALY it was worth spend-
ing approximately £20 million to eliminate all of this
long-term uncertainty in the effect of screening on ovar-
ian cancer mortality. The UKCTOCS triallists’ proposal
to extend follow-up by four additional years is unlikely
to resolve all uncertainty. In this model, the extrapolated
period included 40.9 women-years across the three
screening strategies, whilst the first four years of ex-
trapolation provided 10.7 women-years. Hence, as a
crude approximation, it may be worth spending £5.2
million to extend the UKCTOCS trial by four years. If
willingness to pay values were nearer to the central esti-
mate of cost-effectiveness (£8864 per QALY), as would
happen if the threshold of £13,000 per QALY were used
[27], then estimates of how much should be spent would
increase.
The 2015 UKCTOCS publication, based on a median
of 11.1 years follow-up, found that screening for ovarian
cancer with MMS was associated with a non-significant
ovarian cancer mortality reduction of 15%. The authors
noted that this reduction could be decomposed into a
non-significant reduction of 8% during the first seven
years and a significant reduction of 23% in the last three
years, representing a potential delayed effect of screen-
ing. Our within-trial analysis replicated the finding of no
significant effect. When modelling lifetime outcomes, we
extrapolated a time-varying late treatment effect. This
led to MMS being associated with a significant reduction
in ovarian cancer mortality over a lifetime. However, re-
sults were sensitive to the use of different extrapolation
methods. There also remains the possibility that the ob-
served mortality reduction may reflect a delayed time to
ovarian cancer mortality [28]. If this is the case, then the
mortality effect would vanish over a lifetime horizon.
This extreme possibility is captured within the model
discrepancy sensitivity analysis, for which there is no sig-
nificant difference in ovarian cancer mortality between
screening and not screening.
It is unreasonable to assume that the observed screen-
ing effect will vanish immediately at the 11-year time
point; therefore, we used transparent methods of ex-
trapolation that allowed us to explore the potential
Fig. 2 Cumulative ovarian cancer mortality for different extrapolation methods; MMS and no screening. MMS multimodal screening
Kearns et al. BMC Medicine  (2016) 14:200 Page 7 of 10
impact of alternative estimates of long-term effectiveness
on decision uncertainty. The base-case analysis com-
bined the flexibility of the R-P approach for within-trial
estimates with a novel time-series method for extrapola-
tion. A further innovation of this study was the incorp-
oration of the model discrepancy method within the
extrapolation to account for structural uncertainty asso-
ciated with extrapolation. We are not aware of any other
economic evaluations that have used this innovative
combination.
In addition to the prospective evaluation of extrapola-
tion methods, strengths of our study were the systematic
reviews undertaken to inform the work and the timeliness
of this work. All of the published economic evaluations of
screening for ovarian cancer were conducted prior to the
emergence of data from UKCTOCS on the effect of
screening on mortality, and none used a UK healthcare
perspective. In addition, ours is the first economic evalu-
ation of screening for ovarian cancer to consider HRQoL
as an outcome and so provide a more comprehensive as-
sessment of the potential benefits and harms of screening
for ovarian cancer amongst postmenopausal women. It is
also the first study to estimate the value of further re-
search into screening for ovarian cancer.
Table 3 Estimates of lifetime costs, effects and cost-effectiveness for different extrapolation assumptions
Separate parametric models No screening MMS USS
Costs £143 £588 £782
(95% confidence interval) (£121 to £169) (£425 to £745) (£526 to £1110)
QALYs 14.352 14.376 14.361
(95% confidence interval) (5.100 to 15.922) (5.108 to 15.95) (5.095 to 15.941)
ICER per QALY – £18,372 vs no screening Dominated by MMS
(95% confidence interval) (£7709 to £96,784)
Life years 24.743 24.820 24.818
(95% confidence interval) (24.706 to 24.771) (24.789 to 24.840) (24.786 to 24.839)
Ovarian cancer deaths 1.99% 1.04% 1.05%
(95% confidence interval) (1.65% to 2.45%) (0.85% to 1.34%) (0.87% to 1.37%)
Same parametric models No screening MMS USS
Costs £128 £587 £780
(95% confidence interval) (£109 to £149) (£427 to £745) (£520 to £1105)
QALYs 14.343 14.356 14.341
(95% confidence interval) (5.174 to 15.933) (5.176 to 15.949) (5.166 to 15.94)
ICER per QALY – £36,769 vs no screening Dominated by MMS
(95% confidence interval) (£13,888 to dominated)
Life years 24.778 24.821 24.818
(95% confidence interval) (24.751 to 24.797) (24.789 to 24.84) (24.787 to 24.838)
Ovarian cancer deaths 1.49% 1.03% .05%
(95% confidence interval) (1.29% to 1.77%) (0.85% to 1.35%) (0.86% to 1.36%)
Model discrepancy; 5% per year No screening MMS USS
Costs £179 £614 £851
(95% confidence interval) (£136 to £235) (£440 to £784) (£578 to £1194)
QALYs 14.209 14.244 14.194
(95% confidence interval) (4.671 to 15.903) (4.66 to 15.954) (4.622 to 15.914)
ICER per QALY – £12,643 vs no screening Dominated by MMS
(95% confidence interval) (£3734 to dominated)
Life years 24.659 24.800 24.722
(95% confidence interval) (24.548 to 24.739) (24.591 to 24.863) (24.417 to 24.801)
Ovarian cancer deaths 3.22% 1.99% 3.42%
(95% confidence interval) (2.02% to 5.08%) (0.70% to 4.73%) (1.37% to 7.59%)
ICER incremental cost-effectiveness ratio, QALYs quality-adjusted life years
Kearns et al. BMC Medicine  (2016) 14:200 Page 8 of 10
A limitation of our study was the lack of age and stage
breakdowns for both the incidence of, and mortality
from, ovarian cancer. This limited the analysis in that it
was not possible to use the trial evidence to understand
the natural history of ovarian cancer and thus to esti-
mate the potential cost-effectiveness of alternative
screening strategies, such as different screening intervals
or different age ranges. The key remaining uncertainties
in the health economics of ovarian cancer screening are
the impact of the screening process on HRQoL, the cost
of the ROCA Test and the long-term estimates of the ef-
fect of screening on ovarian cancer mortality. Different
assumptions about how to model this led to twofold and
fourfold increases in the ICER, from £8864 to £18,372
and £36,769.
Conclusions
In conclusion, results from the UKCTOCS demon-
strated that screening for ovarian cancer was associated
with a non-statistically significant effect on ovarian
cancer mortality, based on a median of 11 years of
follow-up. The UKCTOCS triallists called for a further
four years of follow-up to confirm or refute this finding.
Based on 11 years of follow-up we estimated that screen-
ing is not cost-effective, as the mortality benefit is out-
weighed by the dis-benefits associated with both treating
false positives and earlier treatment of women with ovar-
ian cancer. In contrast, lifetime cost-effectiveness results
are promising, with an estimated ICER comparing MMS
with no screening of £8864 per QALY (95% confidence
interval £2600 to £51,576). However, an evaluation of
different extrapolation methods along with value of
information methods showed that there is substantial
uncertainty in the long-term effectiveness of MMS in
reducing ovarian cancer mortality, which is a key driver of
cost-effectiveness.
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